Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Vaccine President Slot Opens Up With McGlynn's Retirement

This article was originally published in The Pink Sheet Daily

Executive Summary

A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.
Advertisement

Related Content

Merck Hires Former CDC Chief Julie Gerberding To Run Its Vaccine Division
Merck Hires Former CDC Chief Julie Gerberding To Run Its Vaccine Division
Merck Hires Julie Gerberding, A Former CDC Chief, To Run Its Vaccine Division
Dow Spin-Off Pfenex Inks Licensing Pact With Merck For Its Protein Technology
Who's the Boss? Merck Names Managerial Team As Schering Merger Looms
Who's the Boss? Merck Names Managerial Team As Schering-Plough Merger Looms
Cervarix, Gardasil Set For FDA Advisory Committee Review
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
Merck/Schering: The Next Wave Of Consolidation
Merck/Schering: The Next Wave Of Consolidation

Topics

Advertisement
UsernamePublicRestriction

Register

PS069780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel